PZ Cormay

PZ Cormay Receivables

The Accounts Receivable of PZ Cormay (CRM.WA) as of Oct 24, 2026 is 12.67 M PLN. In the previous year, Accounts Receivable was 10.94 M PLN — a change of 15.83% (higher).

Receivables

12.67 MPLN

YoY

15.83%

Last updated:

Accounts Receivable of PZ Cormay is 2024 12.67 M PLN. Accounts Receivable of PZ Cormay was 2023 10.94 M PLN. It decreases by 15.83% higher compared to the previous year.

The PZ Cormay Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
13.14 M PLN
Jan 1, 2018
11.19 M PLN
Jan 1, 2019
10.08 M PLN
Jan 1, 2020
10.66 M PLN
Jan 1, 2021
11.27 M PLN
Jan 1, 2022
13.93 M PLN
Jan 1, 2023
10.94 M PLN
Jan 1, 2024
12.67 M PLN
The PZ Cormay Receivables history
YEARReceivablesYoY
12.67 MPLN+15.83%
10.94 MPLN-21.43%
13.93 MPLN+23.56%
11.27 MPLN+5.73%
10.66 MPLN+5.74%
10.08 MPLN-9.90%
11.19 MPLN-14.82%
13.14 MPLN-9.89%
14.58 MPLN+10.72%
13.17 MPLN-25.94%
17.78 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PZ Cormay Stock analysis

What does PZ Cormay do? PZ Cormay SA manufactures diagnostic reagents and laboratory equipment, offering products like biochemical rapid tests, vacuette tubes, and devices including ACCENT-300, ACCENT-200, PRESTIGE 24i, LIVIA analyzers, MYTHIC 18 hematology analyzers, and IChem 100 urinalysis apparatus. The company serves clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation, and specific protein recognition segments. Its products are distributed through Orphee SA, which acquired 100% stake in TT Management Sp z o o on September 1, 2014, to transfer Cormay group's production and distribution activities. Orphee SA, now holding full control of Cormay's operations, manages the distribution of PZ Cormay SA's diagnostic reagents and laboratory equipment. The firm's revenue comes from selling biochemical analyzers, hematology analyzers, and related products to healthcare facilities and laboratories. PZ Cormay SA's product portfolio includes drugs, biochemical rapid tests, and devices such as vacuette tubes, targeting clinical and diagnostic markets with a focus on specialized equipment for medical analysis. The company's revenue streams are derived from the sale of its analytical devices and reagents, with Orphee SA handling the distribution after the 2014 restructuring. PZ Cormay SA's products are used in clinical chemistry, hematology, and other diagnostic segments, with specific equipment like the ACCENT-300 and MYTHIC 18 being key offerings. The restructuring plan transferred production and distribution to Orphee SA, enabling streamlined operations and market access. PZ Cormay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PZ Cormay stock

Accounts Receivable of PZ Cormay is 12.67 M PLN in 2024.

Accounts Receivable of PZ Cormay changed from 10.94 M PLN to 12.67 M PLN, representing a 15.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable PZ Cormay since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's PZ Cormay historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PZ Cormay

All Key Metrics — PZ Cormay